



Effective Date 1/1/2023
Next Review Date... 1/1/2023
Coverage Policy Number IP0498

Acyclovir 5% Ointment for Individual and Family Plans

Table of Contents

Overview 1
Medical Necessity Criteria 1
Reauthorization Criteria 2
Authorization Duration 2
Conditions Not Covered..... 2
Background 2
References 2

Related Coverage Resources

Quantity Limitations (1201)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for acyclovir 5% ointment for Individual and Family Plans that require prior authorization.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Medical Necessity Criteria

Acyclovir 5% ointment is considered medically necessary when ONE of the following are met (1 or 2):

- 1. Genital Herpes. Individual meets BOTH of the following (A and B):
A. Individual is 18 years of age or older
B. There is documentation the individual has had an inadequate response, contraindication, or is intolerant to TWO of the following (i, ii, or iii):

- i. acyclovir capsules (200 mg), tablets (400 or 800 mg), or oral suspension (200 mg/5ml)
- ii. famciclovir tablets (125 mg, 250mg, or 500 mg)
- iii. valacyclovir tablets (500 or 1000 mg)

2. **Mucocutaneous Herpes Simplex Virus infections.** Individual meets **ALL** of the following (A, B, and C):

- A. Individual is 18 years of age or older
- B. Individual is immunocompromised
- C. There is documentation the individual has had an inadequate response, contraindication, or is intolerant to **TWO** of the following (i, ii, or iii):
 - i. acyclovir capsules (200 mg), tablets (400 or 800 mg), or oral suspension (200 mg/5ml)
 - ii. famciclovir tablets (125 mg, 250 mg, or 500 mg)
 - iii. valacyclovir tablets (500 or 1000mg)

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Reauthorization Criteria

Acyclovir 5% ointment (Zovirax) is considered medically necessary for continued use when initial criteria are met AND there is documentation of beneficial response.

Authorization Duration

Initial approval duration: up to 12 months
Reauthorization approval duration: up to 12 months

Conditions Not Covered

Any other use is considered experimental, investigational or unproven, including the following (this list may not be all inclusive):

- Shingles (Herpes Zoster)

Background

OVERVIEW

Professional Societies/Organizations

National guidelines published by the CDC report that the topical antiviral agents offer minimal clinical benefit for genital herpes infections and should not be recommended over the oral antiviral agents (acyclovir, famciclovir, and valacyclovir).⁶

Shingles is a viral infection caused by the varicella zoster virus, the same virus that causes chickenpox.³ The Centers for Disease Control and Prevention cite the use of oral antivirals (acyclovir capsules/tablets/suspension, famciclovir tablets, and valacyclovir caplets) for the treatment of shingles. Oral antivirals speed healing and reduce the risk of complications. Topical antivirals are not noted as treatment options for shingles.

References

1. Zovirax cream [prescribing information]. Bridgewater, NJ: Bausch Health; February 2021.
2. Zovirax ointment [prescribing information]. Bridgewater, NJ: Bausch Health; October 2020.
3. Centers for Disease Control and Prevention – Shingles. Available at: <http://www.cdc.gov/shingles/about/prevention-treatment.html>. Updated July 2019. Accessed on July 8, 2021.
4. Xerese [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; August 2020.

5. Denavir [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; November 2018.
6. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines. MMWR. 2021 June 23;70(4):1-192. Available from: <https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf>. Accessed August 12, 2021.

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.